Fresenius Medical Care AG (FMS): Price and Financial Metrics


Fresenius Medical Care AG (FMS): $14.04

0.08 (+0.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

FMS POWR Grades

  • Stability is the dimension where FMS ranks best; there it ranks ahead of 70.19% of US stocks.
  • FMS's strongest trending metric is Stability; it's been moving down over the last 161 days.
  • FMS ranks lowest in Sentiment; there it ranks in the 0th percentile.

FMS Stock Summary

  • With a price/sales ratio of 0.45, FRESENIUS MEDICAL CARE AG & CO KGAA has a higher such ratio than only 15.27% of stocks in our set.
  • As for revenue growth, note that FMS's revenue has grown -8.95% over the past 12 months; that beats the revenue growth of only 13.78% of US companies in our set.
  • FRESENIUS MEDICAL CARE AG & CO KGAA's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 18.88%, greater than the shareholder yield of 89.34% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to FRESENIUS MEDICAL CARE AG & CO KGAA are ICL, NTWK, ALPP, CO, and CSL.
  • Visit FMS's SEC page to see the company's official filings. To visit the company's web site, go to www.freseniusmedicalcare.com.

FMS Valuation Summary

  • FMS's price/sales ratio is 1.3; this is 88.55% lower than that of the median Healthcare stock.
  • FMS's price/earnings ratio has moved up 12.4 over the prior 243 months.
  • FMS's price/sales ratio has moved up 0.8 over the prior 243 months.

Below are key valuation metrics over time for FMS.

Stock Date P/S P/B P/E EV/EBIT
FMS 2021-08-31 1.3 2.0 19.4 16.3
FMS 2021-08-30 1.3 2.0 19.5 16.4
FMS 2021-08-27 1.3 2.0 19.6 16.4
FMS 2021-08-26 1.3 2.1 19.9 16.6
FMS 2021-08-25 1.3 2.1 19.9 16.6
FMS 2021-08-24 1.3 2.1 20.2 16.8

FMS Growth Metrics

    Its 3 year cash and equivalents growth rate is now at 68.83%.
  • Its 3 year price growth rate is now at -3.5%.
  • The 2 year revenue growth rate now stands at -7.66%.
Over the past 18 months, FMS's revenue has gone down $1,207,128,221.

The table below shows FMS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 20,021.23 2,489.498 1,101.486
2021-09-30 20,199.78 2,404.636 1,067.152
2021-06-30 20,404.96 2,458.608 1,174.364
2021-03-31 21,182.4 3,856.737 1,362.173
2020-12-31 21,647.35 4,233.156 1,411.366
2020-09-30 21,222.2 4,419.68 1,564.352

FMS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FMS has a Quality Grade of B, ranking ahead of 82.76% of graded US stocks.
  • FMS's asset turnover comes in at 0.553 -- ranking 46th of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows FMS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.553 0.310 0.091
2019-12-31 0.591 0.309 0.117
2018-12-31 0.658 0.312 0.236
2018-12-31 0.658 0.312 0.236
2017-12-31 0.698 0.338 0.154
2016-12-31 0.683 0.323 0.155

FMS Stock Price Chart Interactive Chart >

Price chart for FMS

FMS Price/Volume Stats

Current price $14.04 52-week high $36.08
Prev. close $13.96 52-week low $13.69
Day low $14.02 Volume 674,900
Day high $14.25 Avg. volume 689,020
50-day MA $17.59 Dividend yield 3.49%
200-day MA $27.40 Market Cap 8.23B

Fresenius Medical Care AG (FMS) Company Bio


Fresenius Medical Care provides dialysis care services related to the dialysis treatment a patient receives with end stage renal disease, and other health care services. The company was founded in 1996 and is based in Bad Homburg, Germany.


FMS Latest News Stream


Event/Time News Detail
Loading, please wait...

FMS Latest Social Stream


Loading social stream, please wait...

View Full FMS Social Stream

Latest FMS News From Around the Web

Below are the latest news stories about FRESENIUS MEDICAL CARE AG & CO KGAA that investors may wish to consider to help them evaluate FMS as an investment opportunity.

Fresenius Kidney Care Celebrates Nephrology Nurses Week with The CARE Award

Fresenius Kidney Care, the nation's leading provider of kidney care services, is pleased to announce its new annual recognition program to honor frontline nephrology care team members for embodying the company's core values of collaboration, proactivity, reliability, and excellence in care. Fresenius Kidney Care will present The Caring About Renal Excellence (CARE) Award to those who excel in any of the five clinical pillars: quality and safety, growth, clinical leadership, clinical excellence,

Yahoo | September 12, 2022

Fresenius Medical Care partners with National Kidney Foundation Malaysia in kidney health initiative

HONG KONG, September 07, 2022--Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, today signed a memorandum of understanding (MoU) with the National Kidney Foundation (NKF) Malaysia, to work together in promoting kidney health and the prevention of chronic kidney disease amongst children and their families in Malaysia. The organizations will leverage Fresenius Medical Care’s international Corporate Social Responsibility (CSR) initia

Yahoo | September 7, 2022

Fresenius Medical Care Wins Major Award to Support U.S. Veterans with Industry-Leading Dialysis Care

Fresenius Medical North America's (FMCNA) Renal Therapies Group, the leading provider of kidney care products, will be a company of choice to help treat the more than 35,000 military veterans receiving dialysis from the U.S. Department of Veterans Affairs (VA). The VA awarded a five-year contract to FMCNA in five different categories, the most of any medical device company, including home dialysis machines, critical care equipment, water purification systems, and in-center hemodialysis.

Yahoo | August 30, 2022

Fresenius Medical (FMS) Robust Product Portfolio Drives Growth

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Yahoo | August 25, 2022

Fresenius Medical Care Holdings, Inc. -- Moody's affirms Fresenius Medical Care Holdings' Baa3 rating; outlook stable

Rating Action: Moody's affirms Fresenius Medical Care Holdings' Baa3 rating; outlook stableGlobal Credit Research - 15 Aug 2022Frankfurt am Main, August 15, 2022 -- Moody's Investors Service ("Moody's") has today affirmed Fresenius Medical Care Holdings, Inc.'s (FMCH or the company) Baa3 long-term issuer rating. The outlook remains stable.RATINGS RATIONALEToday's rating action reflects the company's standalone credit profile, as well as the fact that FMCH is a significant subsidiary of Fresenius Medical Care AG & Co. KGaA (FMC, Baa3 stable) because this entity owns and consolidates all the US operating subsidiaries of the parent. FMCH contributed around 70% of the parent company's revenue and around 76% of its Moody's adjusted EBITDA in 2021.FMCH's standalone operating profitability a...

Yahoo | August 15, 2022

Read More 'FMS' Stories Here

FMS Price Returns

1-mo -16.87%
3-mo -44.09%
6-mo -57.44%
1-year -59.48%
3-year -53.93%
5-year -69.77%
YTD -56.01%
2021 -20.79%
2020 14.17%
2019 15.01%
2018 -37.85%
2017 25.49%

FMS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full FMS Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6201 seconds.